📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. (2021)

First Author: Simpson CR

Attributed to: Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II) funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41591-021-01408-4

PubMed Identifier: 34108714

Publication URI: http://europepmc.org/abstract/MED/34108714

Type: Journal Article/Review

Volume: 27

Parent Publication: Nature medicine

Issue: 7

ISSN: 1078-8956